A Fast LC-MS/MS Methodology for Estimating Savolitinib in Human Liver Microsomes: Assessment of Metabolic Stability Using In Vitro Metabolic Incubation and In Silico Software Analysis

A Fast LC-MS/MS Methodology for Estimating Savolitinib in Human Liver Microsomes: Assessment of Metabolic Stability Using In Vitro Metabolic Incubation and In Silico Software Analysis

Savolitinib (Orpathys<sup>®</sup>), was developed by (HUTCHMED (Shanghai, China) and, AstraZeneca (Gaithersburg, Maryland, USA), is an inhibitor of the c-Met receptor tyrosine kinase that is orally bioavailable. It was designed for the treatment of pillary and clear-cell renal-cell carci...

Full description

Bibliographic Details
Main Authors: Mohamed W. Attwa, Haitham AlRabiah, Ali S. Abdelhameed, Adnan A. Kadi
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Separations
Subjects:
savolitinib
intrinsic clearance
in vitro half-life
greenness
metabolic stability
P450 metabolic mode
Online Access:https://www.mdpi.com/2297-8739/10/8/450

Similar Items

Similar Items